Oblique Therapeutics Secures SEK 14.1 Million in Rights Issue

The capital injection, finalized on June 30, resulted in the issuance of 7,025,060 new shares, increasing the company's total share count to 63,322,319. Existing shareholders who opted not to participate face a dilution of approximately 11 percent in voting power and capital. The shares were priced at 2.00 SEK each, marking a notable increase from the 1.50 SEK price point set during the firm's 2025 financing round.

CEO Christer Nordstedt characterized the full subscription as a vote of confidence in the company’s strategic direction. The proceeds are earmarked for advancing the firm’s proprietary AbiProt technology platform, which focuses on generating antibodies for difficult drug targets. Chairman Hans Peter Ostler added that the new funding bolsters the company’s ability to move forward with external collaborations and internal project development. Once the Swedish Companies Registration Office registers the capital increase, the interim shares will convert to ordinary stock.